CLCA2

Summary

CLCA2 (chloride channel accessory 2, HGNC:2016) is a protein-coding gene on chromosome 1p22.3, encoding Calcium-activated chloride channel regulator 2 (Q9UQC9). Plays a role in modulating chloride current across the plasma membrane in a calcium-dependent manner, and cell adhesion.

This gene encodes a member of the calcium-activated chloride channel regulator (CLCR) family of proteins. Members of this family regulate the transport of chloride across the plasma membrane. The encoded protein is autoproteolytically processed to generate N- and C- terminal fragments. Expression of this gene is upregulated by the tumor suppressor protein p53 in response to DNA damage. In breast cancer, expression of this gene is downregulated and the encoded protein may inhibit migration and invasion while promoting mesenchymal-to-epithelial transition in cancer cell lines.

Source: NCBI Gene 9635 — RefSeq curated summary.

At a glance

• Gene–disease (curated): heart conduction disease (Moderate, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 161 total
• Druggable target: yes
• MANE Select transcript: NM_006536

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2016
Approved symbol	CLCA2
Name	chloride channel accessory 2
Location	1p22.3
Locus type	gene with protein product
Status	Approved
Aliases	CLCRG2
Ensembl gene	ENSG00000137975
Ensembl biotype	protein_coding
OMIM	604003
Entrez	9635

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000370565, ENST00000490884, ENST00000498802

RefSeq mRNA: 1 — MANE Select: NM_006536 NM_006536

CCDS: CCDS708

Canonical transcript exons

ENST00000370565 — 14 exons

Exon	Start	End
ENSE00000932057	86447508	86447778
ENSE00000932060	86440148	86440325
ENSE00000932061	86438876	86439106
ENSE00000932062	86434518	86434745
ENSE00000932063	86432369	86432528
ENSE00000932065	86428418	86428568
ENSE00000932066	86425339	86425476
ENSE00001186623	86430862	86430970
ENSE00001453032	86455085	86456553
ENSE00001453033	86424171	86424433
ENSE00003589179	86453369	86453602
ENSE00003601334	86441437	86441543
ENSE00003658828	86450563	86450733
ENSE00003683749	86443787	86444011

Expression profiles

Bgee: expression breadth ubiquitous, 176 present calls, max score 99.58.

FANTOM5 (CAGE): breadth broad, TPM avg 5.7085 / max 1020.3016, expressed in 242 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
3845	3.1574	130
3844	1.7545	148
3843	0.3997	113
3842	0.2508	59
3846	0.1461	43

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	99.58	gold quality
gingiva	UBERON:0001828	99.49	gold quality
tongue squamous epithelium	UBERON:0006919	98.88	gold quality
penis	UBERON:0000989	98.74	gold quality
upper leg skin	UBERON:0004262	98.58	gold quality
mammalian vulva	UBERON:0000997	98.56	gold quality
squamous epithelium	UBERON:0006914	98.36	gold quality
oral cavity	UBERON:0000167	98.29	gold quality
esophagus squamous epithelium	UBERON:0006920	97.99	gold quality
hair follicle	UBERON:0002073	97.87	gold quality
upper arm skin	UBERON:0004263	97.83	gold quality
cervix squamous epithelium	UBERON:0006922	97.81	gold quality
cervix epithelium	UBERON:0004801	97.72	gold quality
epithelium of esophagus	UBERON:0001976	97.44	gold quality
bronchial epithelial cell	CL:0002328	97.35	gold quality
esophagus mucosa	UBERON:0002469	96.61	gold quality
skin of hip	UBERON:0001554	96.58	gold quality
pharyngeal mucosa	UBERON:0000355	96.57	gold quality
epithelium of bronchus	UBERON:0002031	95.75	gold quality
bronchus	UBERON:0002185	94.79	gold quality
lower esophagus mucosa	UBERON:0035834	93.96	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	93.51	gold quality
body of tongue	UBERON:0011876	92.68	gold quality
zone of skin	UBERON:0000014	92.67	gold quality
skin of abdomen	UBERON:0001416	92.41	gold quality
epithelium of nasopharynx	UBERON:0001951	92.22	gold quality
skin of leg	UBERON:0001511	91.44	gold quality
nipple	UBERON:0002030	90.71	gold quality
tongue	UBERON:0001723	88.76	gold quality
nasal cavity mucosa	UBERON:0001826	88.10	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	185.47
E-ANND-3	yes	16.84

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI1, TP53

miRNA regulators (miRDB)

64 targeting CLCA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-8082	99.95	67.27	1170
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-374C-5P	99.80	72.06	2910

Literature-anchored findings (GeneRIF, showing 22)

• Expression of hSK4 as well as hCACC-2 and hCACC-3 but not hCACC-1 was demonstrated by reverse transcriptase PCR on native nasal tissues. (PMID:12612194)
• immunohistochemistry clearly demonstrated colocalisation between hCLCA2 and integrin beta4 (PMID:15707651)
• human CLCA2 protein and mRNA expression are elevated during epithelial stratification, suggesting that this protein plays a role in the growth of multi-layered corneal epithelia during both natural development and tissue cultivation. (PMID:16158324)
• Mostly extracellular with only a single transmembrane segment, unlikely to form a channel. (PMID:16873362)
• hCLCA2 Is a p53-Inducible Inhibitor of Breast Cancer Cell Proliferation. (PMID:19654313)
• hCLCA2 is required for epithelial differentiation, and its loss during tumor progression contributes to metastasis. (PMID:21909135)
• the reduced expression of CLCA2 was frequently observed in various kinds of cancers including prostate cancer (PMID:22431922)
• These results strongly suggest that CLCA2 is involved in the p53 tumor suppressor network and has a significant effect on cell migration and invasion. (PMID:22990203)
• CLCA2 expression is higher in squamous cell carcinoma of the lung compared with adenocarcinoma. (PMID:25548429)
• Variants in CLCA2 were associated with an ileal involvement phenotype of Crohn’s disease. (PMID:25557950)
• CLCA2 links junctional adhesion molecule EVA1, to cytosolic signaling proteins that modulate proliferation and differentiation. (PMID:26930581)
• CLCA2 suppress NPC proliferation, migration, invasion and epithelial-mesenchymal transition through inhibiting FAK/ERK signaling. (PMID:29463274)
• identified a new molecular mechanism to explain PCa and MeS link based on CLCA2 repression by CTBP1 and miR-196b-5p molecules that might act as key factors in the progression onset of this disease (PMID:29536528)
• CLCA2 knockdown promoted keratinocyte apoptosis induced by hyperosmotic stress through impairment of cell-cell adhesion. (PMID:29743348)
• we found by calcium imaging that CLCA2 moderately enhanced intracellular-store release but dramatically increased store-operated entry of calcium upon cytosolic depletion (PMID:29758025)
• A novel heterozygous missense mutation c.G1725T of the CLCA2 gene may be associated with heart block disease. (PMID:31326550)
• Genome-wide meta-analysis identified novel variant associated with hallux valgus in Caucasians. (PMID:32131869)
• CLCA2 was identified as a potential prognostic marker for triple negative breast cancer in African American women. (PMID:32298355)
• Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis. (PMID:33966732)
• CLCA2 overexpression suppresses epithelial-to-mesenchymal transition in cervical cancer cells through inactivation of ERK/JNK/p38-MAPK signaling pathways. (PMID:36280802)
• TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2. (PMID:38528613)
• Transport of CLCA2 to the nucleus by extracellular vesicles controls keratinocyte survival and migration. (PMID:38602325)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Clca2	ENSMUSG00000036960
rattus_norvegicus	Clca2	ENSRNOG00000013771

Paralogs (2): CLCA1 (ENSG00000016490), CLCA4 (ENSG00000016602)

Protein

Protein identifiers

Calcium-activated chloride channel regulator 2 — Q9UQC9 (reviewed: Q9UQC9)

Alternative names: Calcium-activated chloride channel family member 2, Calcium-activated chloride channel protein 3

All UniProt accessions (1): Q9UQC9

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in modulating chloride current across the plasma membrane in a calcium-dependent manner, and cell adhesion. Involved in basal cell adhesion and/or stratification of squamous epithelia. May act as a tumor suppressor in breast and colorectal cancer. Plays a key role for cell adhesion in the beginning stages of lung metastasis via the binding to ITGB4.

Subcellular location. Cell membrane. Basal cell membrane. Cell junction Secreted.

Tissue specificity. Expressed in cornea, skin, vagina, esophagus, and larynx (at protein level). Expressed in trachea and mammary gland. Weakly expressed in testis and kidney. Highly expressed in corneal epithelium, colon and trachea. Moderately expressed in brain, urogenital organs, bladder, uterus and prostate. Highly expressed in tissues containing stratified epithelium including cornea, esophagus, larynx, skin and vagina than those tissues which contain only epithelial monolayers. Expressed in normal breast epithelium but not in breast cancer. Highly expressed during epithelial stratification. Expressed in endothelial cells of lung. Expressed selectively in endothelia of small pulmonary arteries, arterioles, and subpleural and interlobular venules.

Post-translational modifications. The 141 kDa mature form is autoproteolytically cleaved by the metalloprotease domain, producing a 109 kDa form and a 35 kDa form. The cleavage is necessary for calcium-activated chloride channel (CaCC) activation activity. N-glycosylated.

Domain organisation. The metalloprotease region is responsible for autoproteolytic processing. It can also cross-cleave other CLCA substrates.

Induction. Significantly down-regulated in breast and colorectal cancer.

Similarity. Belongs to the CLCR family.

RefSeq proteins (1): NP_006527* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002035	VWF_A	Domain
IPR004727	CLCA_chordata	Family
IPR013642	CLCA_N	Domain
IPR036465	vWFA_dom_sf	Homologous_superfamily
IPR051266	CLCR	Family

Pfam: PF08434

UniProt features (31 total): mutagenesis site 6, glycosylation site 5, sequence variant 4, chain 3, binding site 3, sequence conflict 2, topological domain 2, signal peptide 1, site 1, transmembrane region 1, domain 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UQC9-F1	86.87	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 708–709 (cleavage; by autolysis); 165

Ligand- & substrate-binding residues (3): 164; 168; 175

Glycosylation sites (5): 74, 150, 231, 522, 822

Mutagenesis-validated functional residues (6):

Position	Phenotype
150	reduction in size by around 2 kda.
292	no change in size.
522	reduction in size by around 2 kda.
637	no change in size.
822	reduction in size by around 2 kda.
938	no change in size.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2672351	Stimuli-sensing channels

MSigDB gene sets: 117 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, JAEGER_METASTASIS_DN, GOBP_INORGANIC_ANION_TRANSPORT, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_CHLORIDE_TRANSPORT, CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP, HUPER_BREAST_BASAL_VS_LUMINAL_UP, MODULE_99, KEGG_OLFACTORY_TRANSDUCTION, BECKER_TAMOXIFEN_RESISTANCE_DN, chr1p22, RIGGI_EWING_SARCOMA_PROGENITOR_UP, GOBP_TRANSMEMBRANE_TRANSPORT, HOWLIN_CITED1_TARGETS_1_DN, DOANE_BREAST_CANCER_CLASSES_UP

GO Biological Process (6): proteolysis (GO:0006508), cell adhesion (GO:0007155), monoatomic ion transmembrane transport (GO:0034220), monoatomic ion transport (GO:0006811), chloride transport (GO:0006821), chloride transmembrane transport (GO:1902476)

GO Molecular Function (8): metalloendopeptidase activity (GO:0004222), intracellularly calcium-gated chloride channel activity (GO:0005229), chloride channel activity (GO:0005254), metal ion binding (GO:0046872), peptidase activity (GO:0008233), metallopeptidase activity (GO:0008237), ligand-gated monoatomic ion channel activity (GO:0015276), hydrolase activity (GO:0016787)

GO Cellular Component (9): extracellular region (GO:0005576), nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), basal plasma membrane (GO:0009925), cell junction (GO:0030054), nuclear membrane (GO:0031965), anchoring junction (GO:0070161), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Ion channel transport	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
protein metabolic process	1
cellular process	1
monoatomic ion transport	1
transmembrane transport	1
transport	1
monoatomic anion transport	1
inorganic anion transport	1
chloride transport	1
monoatomic anion transmembrane transport	1
endopeptidase activity	1
metallopeptidase activity	1
chloride channel activity	1
ligand-gated monoatomic anion channel activity	1
intracellularly calcium-gated channel activity	1
monoatomic anion channel activity	1
chloride transmembrane transporter activity	1
cation binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
monoatomic ion channel activity	1
ligand-gated channel activity	1
catalytic activity	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
basal part of cell	1
plasma membrane region	1
nucleus	1
nuclear envelope	1
organelle membrane	1
cell junction	1

Protein interactions and networks

STRING

1549 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CLCA2	ANO2	Q9NQ90	973
CLCA2	ANO1	Q5XXA6	925
CLCA2	CFTR	P13569	817
CLCA2	ANO6	Q4KMQ2	657
CLCA2	ITGB4	P16144	631
CLCA2	ANO10	Q9NW15	602
CLCA2	BEST1	O76090	598
CLCA2	BEST2	Q8NFU1	589
CLCA2	LRRC8B	Q6P9F7	550
CLCA2	ANO5	Q75V66	546
CLCA2	CLCN3	P51790	533
CLCA2	SLC12A2	P55011	481
CLCA2	LRRC8A	Q8IWT6	480
CLCA2	ANO7	Q6IWH7	480
CLCA2	ANO9	A1A5B4	479

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CLCA2	H2BC12L	psi-mi:“MI:0915”(physical association)	0.400
CLCA2	NDC1	psi-mi:“MI:0915”(physical association)	0.400
ALB	CNOT1	psi-mi:“MI:0914”(association)	0.350

BioGRID (6): RPS21 (Co-fractionation), NDC1 (Affinity Capture-MS), CLCA2 (Affinity Capture-MS), CLCA2 (Proximity Label-MS), SLC3A2 (Cross-Linking-MS (XL-MS)), CLCA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A0B5GR44, A0A0D3QS97, A1L314, A4IH88, A7MCS3, B9DFR3, E7F0Z8, F4I107, F4I839, O35298, O54728, O80731, P38566, P38567, P38568, P70683, Q03311, Q0P6H9, Q3TTY0, Q3UUQ7, Q3V5L5, Q4V398, Q5GF25, Q5RBP9, Q60963, Q66GM8, Q6DBP4, Q6E279, Q6NQ51, Q75T13, Q765A7, Q765H6, Q812F3, Q84JS1, Q84WF0, Q8BG22, Q8BXJ9, Q8N2E2, Q93ZR8, Q940J8

Diamond homologs: A8K7I4, P54281, Q14CN2, Q2TU62, Q6PT52, Q6Q473, Q8BG22, Q9D7Z6, Q9QX15, Q9TUB5, Q9UQC9, Q55874

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

161 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	143
Likely benign	11
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1851 predictions. Top by Δscore:

Variant	Effect	Δscore
1:86430860:A:AG	acceptor_gain	1.0000
1:86430861:G:GG	acceptor_gain	1.0000
1:86430967:CAAGG:C	donor_loss	1.0000
1:86430968:AAGGT:A	donor_loss	1.0000
1:86430969:AGGTT:A	donor_loss	1.0000
1:86430971:G:GC	donor_loss	1.0000
1:86432368:GGT:G	acceptor_gain	1.0000
1:86432529:G:GG	donor_gain	1.0000
1:86434512:TTCCA:T	acceptor_loss	1.0000
1:86434513:TCCA:T	acceptor_loss	1.0000
1:86434514:CCA:C	acceptor_loss	1.0000
1:86434516:A:T	acceptor_loss	1.0000
1:86434516:AGGT:A	acceptor_gain	1.0000
1:86434517:GGT:G	acceptor_gain	1.0000
1:86434517:GGTG:G	acceptor_gain	1.0000
1:86434602:G:GT	donor_gain	1.0000
1:86438866:T:TA	acceptor_gain	1.0000
1:86438867:G:A	acceptor_gain	1.0000
1:86438871:CATAG:C	acceptor_loss	1.0000
1:86438873:TA:T	acceptor_loss	1.0000
1:86438977:A:T	donor_gain	1.0000
1:86439022:A:T	donor_gain	1.0000
1:86439087:GGCT:G	donor_gain	1.0000
1:86439099:GATT:G	donor_gain	1.0000
1:86443784:CA:C	acceptor_loss	1.0000
1:86443785:A:AG	acceptor_gain	1.0000
1:86443785:AGCTT:A	acceptor_gain	1.0000
1:86443786:G:GG	acceptor_gain	1.0000
1:86443786:GC:G	acceptor_gain	1.0000
1:86443786:GCT:G	acceptor_gain	1.0000

AlphaMissense

6228 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:86430882:T:A	W166R	0.990
1:86430882:T:C	W166R	0.990
1:86453566:T:A	W785R	0.982
1:86453566:T:C	W785R	0.982
1:86430897:T:A	W171R	0.977
1:86430897:T:C	W171R	0.977
1:86432460:T:A	C226S	0.966
1:86432461:G:C	C226S	0.966
1:86434581:T:A	C270S	0.963
1:86434582:G:C	C270S	0.963
1:86425354:G:C	A68P	0.962
1:86447670:G:C	A626P	0.961
1:86447713:T:A	V640D	0.959
1:86425367:T:C	L72P	0.957
1:86430892:T:C	L169P	0.957
1:86430885:G:C	A167P	0.956
1:86447517:T:A	W575R	0.956
1:86447517:T:C	W575R	0.956
1:86430895:G:C	R170P	0.953
1:86432370:T:C	C196R	0.948
1:86432460:T:C	C226R	0.948
1:86455288:G:C	A865P	0.947
1:86430899:G:C	W171C	0.946
1:86430899:G:T	W171C	0.946
1:86434527:T:C	F252L	0.946
1:86434529:T:A	F252L	0.946
1:86434529:T:G	F252L	0.946
1:86447718:G:C	A642P	0.945
1:86447719:C:A	A642D	0.944
1:86430884:G:C	W166C	0.943

dbSNP variants (sampled 300 via entrez): RS1000000026 (1:86436240 G>A,C), RS1000302300 (1:86448321 G>A), RS1000386797 (1:86454800 CAAAACAAAAACA>C,CAAAACA,CAAAACAAAAACAAAAACA), RS1000411676 (1:86448047 C>A,G), RS1000447097 (1:86442100 A>G), RS1000471269 (1:86437042 G>C), RS1000496415 (1:86431499 C>G), RS1000502385 (1:86436593 G>A), RS1000511046 (1:86441239 A>G), RS1000632187 (1:86431871 G>T), RS1000696880 (1:86425167 GT>G,GTT), RS1000819260 (1:86447269 G>A), RS1000886646 (1:86448748 T>A,G), RS1000895859 (1:86443258 A>G), RS1000904487 (1:86449675 G>A,C)

Disease associations

OMIM: gene MIM:604003 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
heart conduction disease	Moderate	Autosomal dominant

Mondo (1): heart conduction disease (MONDO:0000992)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002729_3	Crohn’s disease-related phenotypes	1.000000e-06
GCST009847_1	Hallux valgus	3.000000e-09
GCST009849_2	Hallux valgus	2.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2364708 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Benzo(a)pyrene	increases expression, increases mutagenesis	3
Formaldehyde	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
lead acetate	decreases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
terbufos	increases methylation	1
perfluorooctanoic acid	increases expression	1
zinc chromate	increases abundance, increases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluorohexanesulfonic acid	increases expression	1
nutlin 3	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
incobotulinumtoxinA	increases expression	1
Arsenic Trioxide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cadmium	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	increases expression, affects cotreatment	1
Fonofos	increases methylation	1
Estradiol	affects cotreatment, decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
Lucanthone	increases expression	1
Methyl Methanesulfonate	increases expression	1
Parathion	increases methylation	1
Vanadates	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E7X0	HEK-293 hCLCA2	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.